Jelena Kresoja-Rakic

Dr. Jelena Kresoja-Rakic


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ARArun Renganathan
Arun Renganathan
JKJelena Kresoja-Rakic
Jelena Kresoja-Rakic
NENohemy Echeverry
Nohemy Echeverry
GZGabriela Ziltener
Gabriela Ziltener
BVBart Vrugt
Bart Vrugt
Emanuela Felley-BoscoEmanuela Felley-Bosco
Emanuela Felley-Bosco
Malignant pleural mesothelioma (MPM) is an aggressive cancer with short overall survival. Long non-coding RNAs (lncRNA) are a class of RNAs more than 200 nucleotides long that do not code for protein and are part of the 90% of the human genome that is transcribed. Earlier experimental studies in mice showed GAS5 (growth arrest specific transcript 5) gene deletion in asbestos driven mesothelioma. GAS5 encodes for a lncRNA whose function is not well known, but it has been shown to act as glucocorticoid receptor decoy and microRNA “sponge”. Our aim was to investigate the possible role of the GAS5 in the growth of MPM.

1 November 2019 in Trends in Genetics
Verified
Journal Article
Open access
JKJelena Kresoja-Rakic
Jelena Kresoja-Rakic
RSRaffaella Santoro
Raffaella Santoro
The nucleolus is the largest substructure in the nucleus and forms around the nucleolar organizer regions (NORs), which comprise hundreds of rRNA genes. Recent evidence highlights further functions of the nucleolus that go beyond ribosome biogenesis. Data indicate that the nucleolus acts as a compartment for the location and regulation of repressive genomic domains and, together with the nuclear lamina, represents the hub for the organization of the inactive heterochromatin. In this review, we discuss recent findings that have revealed how nucleolar structure and rRNA gene chromatin states are regulated during early mammalian development and their contribution to the higher-order spatial organization of the genome.

18 February 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
MWMarco Wachtel
Marco Wachtel
JKJelena Kresoja-Rakic
Jelena Kresoja-Rakic
MOMichal Okoniewski
Michal Okoniewski
PBPeter Bode
Peter Bode
FNFelix Niggli
Felix Niggli
Beat SchaeferBeat Schaefer
Beat Schaefer
Biological heterogeneity represents a major obstacle for cancer treatment. Therefore, characterization of treatment‐relevant tumor heterogeneity is necessary to develop more effective therapies in the future. Here, we uncovered population heterogeneity among PAX/FOXO1‐positive alveolar rhabdomyosarcoma by characterizing prosurvival networks initiated by FGFR4 signaling. We found that FGFR4 signaling rescues only subgroups of alveolar rhabdomyosarcoma cells from apoptosis induced by compounds targeting the IGF1R‐PI3K‐mTOR pathway. Differences in both proapoptotic machinery and FGFR4‐activated signaling are involved in the different behavior of the phenotypes. Proapoptotic stress induced by the kinase inhibitors is sensed by Bim/Bad in rescue cells and by Bmf in nonrescue cells. Anti‐apoptotic ERK1/2 signaling downstream of FGFR4 is long‐lasting in rescue and short‐termed in most non‐rescue cells. Gene expression analysis detected signatures specific for these two groups also in biopsy samples. The different cell phenotypes are present in different ratios in alveolar rhabdomyosarcoma tumors and can be identified by AP2β expression levels. Hence, inhibiting FGFR signaling might represent an important strategy to enhance efficacy of current RMS treatments.

2 June 2022 in Developmental Dynamics
Verified
Journal Article
Closed access
RLRobert L. Lalonde
Robert L. Lalonde
CKCassie L. Kemmler
Cassie L. Kemmler
FRFréderike W. Riemslagh
Fréderike W. Riemslagh
AAAndrew J. Aman
Andrew J. Aman
JKJelena Kresoja-Rakic
Jelena Kresoja-Rakic
CMChristian Mosimann
Christian Mosimann

1 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
JKJelena Kresoja-Rakic
Jelena Kresoja-Rakic
EKEsra Kapaklikaya
Esra Kapaklikaya
GZGabriela Ziltener
Gabriela Ziltener
DDDamian Dalcher
Damian Dalcher
RSRaffaella Santoro
Raffaella Santoro
Emanuela Felley-BoscoEmanuela Felley-Bosco
Emanuela Felley-Bosco
Identification of cis- and trans-acting elements regulating calretinin expression in mesothelioma cells

23 February 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
KOKathrin Oehl
Kathrin Oehl
JKJelena Kresoja-Rakic
Jelena Kresoja-Rakic
IOIsabelle Opitz
Isabelle Opitz
BVBart Vrugt
Bart Vrugt
WWWalter Weder
Walter Weder
Emanuela Felley-BoscoEmanuela Felley-Bosco
Emanuela Felley-Bosco
Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained in vitro, providing a useful tool to investigate underlying mechanisms. Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naive patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort. Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed in vivo, which eventually may lead to a more logical approach for developing new treatment strategies.